Vyluma’s therapeutic focus is on the clinical development of ophthalmic treatments for disease states with limited treatment options.  In partnership with eye care clinicians, we are focused on transforming the current standard of care beginning with our late stage product candidate NVK002 to treat pediatric myopia.